Response to: 'Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future' by Wang et al
Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al' by Pino et al
Ouldali N, Pouletty M, Lokmer J, Benzouid C, Beyler C, Deho A, Meinzer U, Faye A, Melki I; Great Paris Region (GPR) Kawa-COVID-19 consortium.
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothes
Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A.
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Scarsi M, Piantoni S, Colombo E, Air√≥ P, Richini D, Miclini M, Bertasi V, Bianchi M, Bottone D, Civelli P, Cotelli MS, Damiolini E, Galbassini G, Gatta D, Ghirardelli ML, Magri R, Malamani P, Mendeni M, Molinari S, Morotti A, Salada L, Turla M, Vender A, Tincani A, Brucato A, Franceschini F, Furloni R, Andreoli L.
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation pr
Khan A, Cole A, Bhadauria N, El-Hassan M, Abdulla D, Axon T, Fattah Z, Manson JJ, Moreno-Cuesta J, Mukerjee D.
Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al
Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J.
Improving telemedicine and in-person management of rheumatic and autoimmune diseases,during and after COVID-19 pandemic outbreak. Definite need for more Rheumatologists. Response to: 'Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?' by A
Caso F, Del Puente A, Girolimetto N, Tasso M, Caso C, Scarpa R, Costa L.
Comment on: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al
Karahan S, Cetinkaya A, Aydin K, Aslan Sirakaya H.
Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients with Systemic Lupus Erythematosus
Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM; NYU WARCOV Investigators.
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients
Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, Guidelli G, Albano G, Folci M, Squadroni M, Beretta GD, Ciccarelli M, Castoldi M, Lleo A, Aghemo A, Vernile L, Malesci A, Omodei P, Angelini C, Badalamenti S, Cecconi M, Cremonesi A, Selmi C; Humanitas and Gavazzeni / Castelli COVID-19 Task Forces.
Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt
Gheita TA, Salem MN, Eesa NN, Khalil NM, Gamal NM, Noor RA, Moshrif AH, Shereef RE, Ismail F, Noshy N, Fawzy RM, Elshebini E, Khalifa I, Saadany HE, Tharwat S, El-Najjar A, Fattah YA, Sallam R, El-Bahnasawy AS, Gharbia O, Hassan E, ElShanawany A, Mohamed EF, Senara S, Ismail M, Nasef SI, Abdalla AM, Elessawi D, Fawzy SM, Alfadl EA, Khalifa A, Abaza NM; ECR COVID19-Study Group.
American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, F Son MB, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ.
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India
Goyal M, Patil P, Pathak H, Santhanam S, Goel A, Sharma V, Pandey A, Gupta N, Jain R, Akerkar S, Das P, Dudam R, Mendiratta N, Pandey BD, Cb M, Singh BK, Kumar S, Nolkha N, Jain S, Jain S, Sharma A, Misra DP.
Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Mareno et al
The course of Covid 19 in Inflammatory Bowel Disease: protective role of TNF antagonists Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
The Risk of Respiratory Tract Infections in Psoriasis Patients Treated With IL-23-pathway Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision-Making During the COVID-19 Pandemic
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L; SARI-RAF Study Group; SARI-RAF Study Group members.
Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Pl√º√ü et al
COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic
Akintayo RO, Akpabio A, Kalla A, Dey D, Migowa A, Olaosebikan H, Bahiri R, El Miedany Y, Hadef D, Hamdi W, Oyoo O, Slimani S, Yerima A, Taha Y, Adebajo A, Adelowo O, Tikly M, Ghozlani I, Abdelghani KB, Fouad NA, Mosad D, El Mikkawy D, Abu-Zaid MH, Abdel-Magied RA; COVID-19 African Rheumatology Study Group.
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
Nu√±o L, Novella Navarro M, Bonilla G, Franco-G√≥mez K, Aguado P, Peiteado D, Monjo I, Tornero C, Villalba A, Miranda-Carus ME, De Miguel E, Bogas P, Castilla-Plaza A, Bernad-Pineda M, Garc√≠a-Lorenzo E, Rodr√≠guez-Araya T, Balsa A.
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
Mendel A, Bernatsky S, Askanase A, Bae SC, Clarke AE, Costedoat-Chalumeau N, Gladman DD, Gordon C, Hanly J, Jacobsen S, Kalunian K, Mak A, Mosca M, Pons-Estel BA, Ruiz-Irastorza G, Urowitz M, Vinet √â.
Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So et al
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al
Schulze-Koops H, Krueger K, Specker C; Kommission Pharmakotherapie of the German Society of Rheumatology.
Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie et al
Gamboa-Alonso CM, Figueroa-Parra G, Galarza-Delgado DA.
Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al
Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot pot' versus in US 'hot pot': similarity and difference' by Zhao et al
D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Sparks JA, Wallace ZS.
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrej√≥n I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena V√°zquez N, Mera Varela A, Retuerto M, Seijas-Lopez A.
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients
Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, Cozzi G, Depascale R, Zanatta E, Gasparotto M, Benvenuti F, Bindoli S, Gatto M, Felicetti M, Ortolan A, Campaniello D, Larosa M, Lorenzin M, Ramonda R, Sfriso P, Schiavon F, Iaccarino L, Doria A.
Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation
Woodruff M, Ramonell R, Cashman K, Nguyen D, Ley A, Kyu S, Saini A, Haddad N, Chen W, Howell JC, Ozturk T, Lee S, Estrada J, Morrison-Porter A, Derrico A, Anam F, Wu H, Le S, Jenks S, Hu W, Lee FE, Sanz I.
Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic
Konig MF, Gianfrancesco M, Yazdany J, Robinson PC.
No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al
Response to: Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al
Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P.
Two False Negative Test Results in a Symptomatic Patient with a Confirmed Case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)
Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M.
Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy
Quartuccio L, Valent F, Pasut E, Tascini C, Vita S.
Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition
Turner D, Huang Y, Mart√≠n-de-Carpi J, Aloi M, Focht G, Kang B, Zhou Y, Sanchez C, Kappelman MD, Uhlig HH, Pujol-Muncunill G, Ledder O, Lionetti P, Dias JA, Ruemmele FM, Russell RK; Paediatric IBD Porto group of ESPGHAN.
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A.
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Michelena X, Borrell H, L√≥pez-Corbeto M, L√≥pez-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Ant√≥n S, A√±ez GA, Caparr√≥s-Ruiz R, Pluma A, Trallero-Aragu√°s E, Barcel√≥-Bru M, Almirall M, De Agust√≠n JJ, Segura JL, Juli√† A, Marsal S.
Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients
The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al.
Response to: 'Patients with lupus are not protected from COVID-19: a comment' by Sawalha, 'No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit' by RomâˆšÂ£o et al and 'SLE patients are not immune to COVID-19: importance of s...
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al.
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, de Paulis A, Denton CP, Distler O, Fox D, Furst DE, Khanna D, Krieg T, Kuwana M, Lee EB, Li M, Pillai S, Wang Y, Zeng X, Taliani G.
[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid¬†19 pandemic].
Schulze-Koops H, Holle J, Moosig F, Specker C, Aries P, Burmester G, Fiehn C, Hoyer B, Krause A, Leipe J, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wager U, Kr√ºger K, Iking-Konert C; im Auftrag der Kommission Pharmakotherapie und des Vorstandes der Deutschen Gesellschaft f√ºr Rheumatologie..
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?...
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
[A¬†cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].
Schmeiser T, Broll M, Dormann A, Fr√§bel C, Hermann W, Hudowenz O, Keil F, M√ºller-Ladner U, √ñzden F, Pfeiffer U, Saech J, Schwarting A, Stapfer G, Steinchen N, Storck-M√ºller K, Strunk J, Thiele A, Triantafyllias K, Wassenberg S, Wilden E, Hasseli R.
Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist.
Graef ER, Liew JW, Putman MS, Simard JF, Sirotich E, Berenbaum F, Duarte-Garc√≠a A, Grainger R, Harrison C, Konig MF, Korsten P, Proulx L, Richards DP, Robinson PC, Sattui SE, Ugarte-Gil MF, Young KJ, Kim AH, Sparks JA; COVID-19 Global Rheumatology Alliance..
COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN.
Turner D, Huang Y, Mart√≠n-de-Carpi J, Aloi M, Focht G, Kang B, Zhou Y, Sanchez C, Kappelman MD, Uhlig HH, Pujol-Muncunill G, Ledder O, Lionetti P, Dias JA, Ruemmele FM, Russell RK; Paediatric IBD Porto group of ESPGHAN..